Complimentary CME Dinner Symposium
New Hope on the Horizon: Advances in the Diagnosis and Treatment of Idiopathic Hypersomnia

Monday, June 5, 2023
6:30 pm – 7:00 pm Registration and Dinner
7:00 pm – 8:30 pm Symposium

JW Marriott Indianapolis |
Room: JW Grand Ballroom 5
10 S West St, Indianapolis, IN 46204

Earn 1.5 CME/CE Credits


6:30 pm - 7:00 pm

Registration and Dinner

7:00 pm - 7:10 pm

Introduction and Opening Remarks

7:10 pm - 7:25 pm

IH: Overview, Symptoms, and Disease Burden

7:25 pm - 7:40 pm

Diagnosis of IH

7:40 pm - 7:55 pm

Current IH Treatment

7:55 pm - 8:10 pm

New and Emerging Treatment Options

8:10 pm - 8:30 pm

Concluding Remarks, Takeaways, and Q&A

Program Description

Idiopathic hypersomnia (IH) is a chronic neurological disorder that has significant impacts on daily functioning, with symptoms that include, but often go beyond excessive daytime sleepiness (EDS).

Overall awareness about IH remains low, which contributes to the suboptimal recognition of this condition, which is often exacerbated by insufficient diagnostic criteria leading to delayed diagnosis and treatment.

Until recently, there was no FDA approved treatment option for IH, and historically, although IH is not the same as narcolepsy, the same treatment options were offered, leading to suboptimal treatment response and exacerbation of disease burden. Recent advances, with a new option now approved and other agents in development, can help close some of the current gaps.

This symposium will offer expert perspectives on the impact of IH, as well as best practices and advances for its screening, diagnosis, and treatment.

Presented by:

Michael J. Thorpy, MD
Michael J. Thorpy, MD
Yves Dauvilliers, MD, PhD
Yves Dauvilliers, MD, PhD


Seth S. Martin, MD, MHS
Michael Ezrokhi, PhD
Fátima Rodriguez, MD, MPH


Pre-Register below to be added to our VIP attendance list and be given priority to join this event. Registration to this event is complimentary, however you must be a registered attendee of the SLEEP 2023.


   PACE Logo

This activity is jointly provided by Partners for Advancing Clinical Education and Cardiometabolic Health Congress. This satellite symposium is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Expert Perspectives and Discussions: What You Need to Know About Optimizing Cardiorenal Outcomes with Novel Non-Steroidal MRAs

Sunday, November 6, 2022

7:30 p.m. – 9:00 p.m.

Marriott Marquis

Location: Great Lakes EF

2121 South Prairie Avenue,

Chicago IL, 60616

US-based healthcare professionals, including cardiologists, primary care physicians, endocrinologists, lipidologists as well as nurses, nurse practitioners, and pharmacists.

This activity is supported by educational grant from Bayer HealthCare Pharmaceuticals Inc.

After completing this activity, the participant should be better able to:

  • Recognize the burden of comorbid CKD and T2DM as a major driver of cardiovascular and renal morbidity and mortality.
  • Identify T2DM patients at risk for kidney disease or kidney disease progression based on recommended diagnostic practices.
  • Summarize the efficacy, safety, and mechanisms of action of nonsteroidal MRAs and other emerging treatment options for DKD.
  • Select tailored treatment regimens that reduce the risk of cardiorenal adverse events in T2DM patients with CKD.

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress. 


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress.  Global is accredited by the ACCME to provide continuing medical education for physicians.


Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.5 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


 Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

Credit Designation

Global Education Group designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number (UAN): 0530-9999-22-241-L01-P.

This is a knowledge-based activity.

For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].

More information on this to come.  

Information on planner and faculty disclosure will be made available soon.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.